Organogenesis Holdings Inc (ORGO) concluded trading on Thursday at a closing price of $4.25, with 0.49 million shares of worth about $2.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 34.49% during that period and on July 03, 2025 the price saw a gain of about 4.94%. Currently the company’s common shares owned by public are about 126.85M shares, out of which, 64.15M shares are available for trading.
Stock saw a price change of 17.73% in past 5 days and over the past one month there was a price change of 51.25%. Year-to-date (YTD), ORGO shares are showing a performance of 57.41% which increased to 32.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $6.71 during that period. The average intraday trading volume for Organogenesis Holdings Inc shares is 1.43 million. The stock is currently trading 24.02% above its 20-day simple moving average (SMA20), while that difference is up 17.23% for SMA50 and it goes to 16.18% higher than SMA200.
Organogenesis Holdings Inc (NASDAQ: ORGO) currently have 126.85M outstanding shares and institutions hold larger chunk of about 51.46% of that.
The stock has a current market capitalization of $539.13M and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$0.15 in the same period. It has Quick Ratio of 3.67 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ORGO, volatility over the week remained 6.44% while standing at 6.58% over the month.
Stock’s fiscal year EPS is expected to rise by 754.67% while it is estimated to increase by 199.16% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Lake Street on June 28, 2024 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by Cantor Fitzgerald stated Organogenesis Holdings Inc (ORGO) stock as an Overweight in their note to investors on February 07, 2024, suggesting a price target of $5 for the stock. On June 15, 2023, Morgan Stanley Initiated their recommendations, while on May 24, 2023, BTIG Research Upgrade their ratings for the stock with a price target of $10. Stock get a Neutral rating from BTIG Research on November 10, 2022.
